A carregar...
A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants
Trikafta, a triple-combination drug, consisting of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor) and the gating potentiator VX-770 (ivacaftor) provided unprecedented clinical benefits for patients with the most common cystic fibrosis (CF) mutation, F508del. Trikafta indications were r...
Na minha lista:
| Publicado no: | J Pers Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8307171/ https://ncbi.nlm.nih.gov/pubmed/34357110 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11070643 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|